Neurotrophin-3 promotes proliferation and cholinergic neuronal differentiation of bone marrow- derived neural stem cells via notch signaling pathway

Yan, Yi; Li, Shao-heng; Gao, Zhong; Zou, Safeng; Li, Hongyan; Tao, Zhenyu; Song, Jié; Yang, Jingxian

doi:10.1016/j.lfs.2016.10.004

Cited by 29 publications

(16 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, PL has been shown to provide an increase to the growth rates of MSC populations grown outside of fetal bovine serum, while still ensuring the chromosomal stability of the cell line over multiple generation. Moreover, additional trophic factors which improve the proliferation and differentiation of BM-MSCs into neurons and neuron-like cells in vitro have been identified, including melatonin, ATP, neurotrophin-3 (NT-3), rolipram, β-mercaptoethanol (BME), CHIR99021 (CHIR), lithium chloride, and others (Tu et al, 2014; Abdullah et al, 2016; Joe and Cho, 2016; Narcisi et al, 2016; Shuai et al, 2016; Yan et al, 2016). Co-culturing BM-MSCs with active neurons or culturing BM-MSCs on media conditioned by mature neurons also appears to promote their differentiation towards neural cell types (Tu et al, 2014; Kil et al, 2016).…”

Section: Identifying the Optimal Cell Type For Stem Cell Transplanmentioning

confidence: 99%

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms

Stonesifer

Corey

Ghanekar

et al. 2017

Progress in Neurobiology

198

207

View full text Add to dashboard Cite

Ischemic stroke is a leading cause of death worldwide. A key secondary cell death mechanism mediating neurological damage following the initial episode of ischemic stroke is the upregulation of endogenous neuroinflammatory processes to levels that destroy hypoxic tissue local to the area of insult, induce apoptosis, and initiate a feedback loop of inflammatory cascades that can expand the region of damage. Stem cell therapy has emerged as an experimental treatment for stroke, and accumulating evidence supports the therapeutic efficacy of stem cells to abrogate stroke-induced inflammation. In this review, we investigate clinically relevant stem cell types, such as hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs), very small embryonic-like stem cells (VSELs), neural stem cells (NSCs), extraembryonic stem cells, adipose tissue-derived stem cells, breast milk-derived stem cells, menstrual blood-derived stem cells, dental tissue-derived stem cells, induced pluripotent stem cells (iPSCs), teratocarcinoma-derived Ntera2/D1 neuron-like cells (NT2N), c-mycER(TAM) modified NSCs (CTX0E03), and notch-transfected mesenchymal stromal cells (SB623), comparing their potential efficacy to sequester stroke-induced neuroinflammation and their feasibility as translational clinical cell sources. To this end, we highlight that MSCs, with a proven track record of safety and efficacy as a transplantable cell for hematologic diseases, stand as an attractive cell type that confers superior anti-inflammatory effects in stroke both in vitro and in vivo. That stem cells can mount a robust anti-inflammatory action against stroke complements the regenerative processes of cell replacement and neurotrophic factor secretion conventionally ascribed to cell-based therapy in neurological disorders.

show abstract

Section: Identifying the Optimal Cell Type For Stem Cell Transplanmentioning

confidence: 99%

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms

Stonesifer

Corey

Ghanekar

et al. 2017

Progress in Neurobiology

198

207

View full text Add to dashboard Cite

show abstract

“…The results of differentiation experiments showed that BME is a good inducer of neurogenesis in AMSCs. Several supplementary trophic factors enhanced cell growth and neuronal differentiation in AMSCs in vitro, including melatonin, BME, CHIR99021, neurotrophin-3, and lithium chloride (27)(28)(29)(30)(31)(32). BME, which is an antioxidant reagent, was most commonly used at low concentrations for cell differentiation and therapy (33).…”

Section: Discussionmentioning

confidence: 99%

Differentiation of Adipose-Derived Mesenchymal Stem Cells into Neuron-Like Cells induced by using β-mercaptoethanol

et al. 2020

View full text Add to dashboard Cite

Background: Adipose derived-mesenchymal stem cells have been used as an alternative to bone marrow cells in this study. Objective: We investigated the in vitro isolation, identification, and differentiation of stem cells into neuron cells, in order to produce neuron cells via cell culture, which would be useful in nerve injury treatment. Method: Mouse adipose mesenchymal stem cells were dissected from the abdominal subcutaneous region. Neural differentiation was induced using β-mercaptoethanol. This study included two different neural stage markers, i.e. nestin and neurofilament light-chain, to detect immature and mature neurons, respectively. Results: The immunocytochemistry results showed that the use of β-mercaptoethanol resulted in the successful production of neuron cells. This was attributable to the increase and significant overexpression of the nestin protein during the early exposure period, which resulted in the expression of the highest levels of nestin. In comparison, the expression level of neurofilament light-chain protein also increased with time but less than nestin. Non-treated mesenchymal stem cells, considered as control showed very low expression for both markers. Conclusion: The results of this study indicate that adipose mesenchymal cells represent a good, easily obtainable source of bone marrow cells used to developing the differentiation process.

show abstract

“…MSCs can be primed to differentiate into specific neural lineages [107][108][109][110][111][112] Optimization of MSC neural differentiation Chronic stroke…”

Section: Acute Strokementioning

confidence: 99%

Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury

et al. 2020

View full text Add to dashboard Cite

Acquired brain injury (ABI) entails any injury that disrupts neuronal activity and is not degenerative, hereditary, congenital, or induced by birth trauma. Traditional examples of ABI include not only stroke and traumatic brain injury (TBI), but also near drowning, aneurysm, tumor, meningitis and other infections involving the brain, and injuries resulting from lack of oxygen supply to the brain, such as those seen in myocardial infarction. ABI may involve a structural insult, changes to metabolic activity, or disruption to neuronal capabilities.While progressive loss of brain cells and debilitating motor and cognitive deficits play a role in all these disorders, stroke and TBI overlap particularly closely in pathology and impose an immense burden on the American and global populations. AbstractIschemic stroke and traumatic brain injury (TBI) comprise two particularly prevalent and costly examples of acquired brain injury (ABI). Following stroke or TBI, primary cell death and secondary cell death closely model disease progression and worsen outcomes. Mounting evidence indicates that long-term neuroinflammation extensively exacerbates the secondary deterioration of brain structure and function. Due to their immunomodulatory and regenerative properties, mesenchymal stem cell transplants have emerged as a promising approach to treating this facet of stroke and TBI pathology. In this review, we summarize the classification of cell death in ABI and discuss the prominent role of inflammation. We then consider the efficacy of bone marrow-derived mesenchymal stem/stromal cell (BM-MSC) transplantation as a therapy for these injuries. Finally, we examine recent laboratory and clinical studies utilizing transplanted BM-MSCs as antiinflammatory and neurorestorative treatments for stroke and TBI. Clinical trials of BM-MSC transplants for stroke and TBI support their promising protective and regenerative properties. Future research is needed to allow for better comparison among trials and to elaborate on the emerging area of cell-based combination treatments. K E Y W O R D Sbone marrow-derived mesenchymal stem cells, clinical trials, inflammation, ischemic stroke, preclinical studies, traumatic brain injury

show abstract

Neurotrophin-3 promotes proliferation and cholinergic neuronal differentiation of bone marrow- derived neural stem cells via notch signaling pathway

Cited by 29 publications

References 56 publications

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms

Differentiation of Adipose-Derived Mesenchymal Stem Cells into Neuron-Like Cells induced by using β-mercaptoethanol

Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury

Contact Info

Product

Resources

About